What it's for (Indications)
- Hydrocortisone and miconazole topical combination cream is primarily indicated for the treatment of inflammatory dermatomycoses, which are fungal infections of the skin accompanied by significant inflammation, pruritus, and erythema.
- This includes conditions such as tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete's foot) when these are complicated by inflammatory symptoms that necessitate the use of a corticosteroid.
- The miconazole component provides broad-spectrum antifungal activity against dermatophytes (e.
- g.
- , Trichophyton, Epidermophyton, Microsporum) and yeasts (e.
- g.
- , Candida species), while hydrocortisone, a mild corticosteroid, works to rapidly reduce the associated inflammation, redness, swelling, and itching.
- This dual-action formulation aims to relieve symptoms quickly while eradicating the underlying fungal infection, leading to more effective and comfortable treatment for patients.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and pediatric patients aged 2 years and older, the typical dosage regimen involves applying a thin layer of the hydrocortisone and miconazole topical cream to the affected skin area twice daily, usually in the morning and evening. The cream should be gently massaged into the skin until it is fully absorbed. Treatment duration generally ranges from two to four weeks, depending on the severity and type of infection, and the patient's response to therapy. It is crucial for patients to complete the full course of treatment as prescribed, even if symptoms improve earlier, to prevent recurrence. Prolonged use beyond the recommended duration or application to large body surface areas should be avoided without strict medical supervision due to the potential for systemic absorption of hydrocortisone. The use of occlusive dressings over the treated area is generally not recommended as it can enhance systemic absorption and increase the risk of adverse effects. |
Safety & Warnings
Common Side Effects
- Common local side effects associated with hydrocortisone and miconazole topical may include mild burning, stinging, itching, irritation, or redness at the application site.
- These reactions are usually transient and tend to subside with continued use.
- However, more prolonged or extensive use, especially under occlusive dressings or on sensitive skin areas, can lead to corticosteroid-related adverse effects such as skin atrophy (thinning), striae (stretch marks), telangiectasias (spider veins), acneiform eruptions, folliculitis, hypertrichosis (excessive hair growth), and perioral dermatitis.
- Systemic absorption of hydrocortisone, though rare with short-term topical use, can potentially lead to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, or glycosuria, particularly in children or when applied to large areas or compromised skin.
- Miconazole can occasionally cause local irritation or allergic contact dermatitis.
- If severe irritation or signs of systemic effects develop, treatment should be discontinued, and a healthcare professional consulted.
Serious Warnings
- Black Box Warning: Serious Warnings: Topical hydrocortisone and miconazole combination products do not carry a formal FDA Black Box Warning. However, serious warnings regarding potential risks are critical for patient safety and healthcare provider awareness. **Adrenal Suppression and Systemic Effects:** Although systemic absorption of topical corticosteroids is generally low, it can occur, leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glycosuria. This risk is amplified with prolonged use, application to large surface areas, use under occlusive dressings, in individuals with impaired skin barrier function, and particularly in pediatric patients who have a higher skin surface area to body weight ratio. Patients, especially children, should be periodically evaluated for HPA axis suppression via appropriate diagnostic tests. If HPA axis suppression is noted, attempts should be made to withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. **Infection Exacerbation/Masking:** The corticosteroid component can mask clinical manifestations of existing skin infections (bacterial, viral, parasitic) or allow for their exacerbation due to local immunosuppression. It is crucial to ensure that the primary infection is fungal and that appropriate antifungal therapy (miconazole) is sufficient to control the fungal component. If concurrent bacterial infection is present, appropriate antibacterial therapy should be instituted. **Hypersensitivity Reactions:** While rare, allergic contact dermatitis or other hypersensitivity reactions to either hydrocortisone, miconazole, or excipients can occur. If irritation, burning, stinging, or other signs of hypersensitivity develop, discontinue treatment and consult a healthcare professional. These warnings underscore the importance of judicious use, careful patient selection, and ongoing monitoring during therapy.
- Patients should be advised against using hydrocortisone and miconazole topical for longer than the prescribed duration or on large body surface areas, particularly without medical supervision, due to the risk of systemic corticosteroid effects, including adrenal suppression.
- This risk is elevated in children, who have a larger skin surface area to body weight ratio, and in patients using occlusive dressings.
- The medication is for external use only and should not be applied to the eyes or ingested.
- If irritation or sensitization occurs with the use of the cream, treatment should be discontinued, and appropriate therapy instituted.
- Long-term continuous topical corticosteroid therapy should be avoided, especially in infants and children, as it may interfere with growth and development.
- This product is not intended for the treatment of viral infections (e.
- g.
- , herpes simplex, varicella) or specific bacterial infections, as the corticosteroid component may mask or exacerbate these conditions.
- Care should be taken when applying to the face, groin, or axillae, as these areas are more susceptible to corticosteroid-induced skin changes.
How it Works (Mechanism of Action)
The therapeutic action of this combination cream is derived from its two active pharmaceutical ingredients: hydrocortisone and miconazole. Hydrocortisone, a low-potency corticosteroid, exerts its effects primarily through its anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. This effectively reduces the redness, swelling, and itching associated with inflammatory skin conditions. Miconazole, an azole antifungal agent, exerts its fungicidal and fungistatic actions by inhibiting the biosynthesis of ergosterol, an essential component of the fungal cell membrane. This inhibition leads to structural and functional impairment of the fungal cell membrane, resulting in increased permeability, leakage of cellular contents, and ultimately cell death. Together, these two agents provide symptomatic relief from inflammation while simultaneously treating the underlying fungal infection.
Commercial Brands (Alternatives)
No other brands found for this formula.